Skip to main content
Back
PRGO logo

Perrigo Company plc

Data quality: 100%
PRGO
NYSE Healthcare Drug Manufacturers - Specialty & Generic
$9.64
▲ $0.07 (0.73%)
Mkt Cap: 1.33B
Day Range
$9.31 $9.81
52-Week Range
$9.23 $28.44
Volume
2,514,216
50D / 200D Avg
$13.28 / $19.16
Prev Close
$9.57

Price History

Financial Trends

Peer Comparison

vs Healthcare sector median (627 peers)

Metric Stock Sector Median
P/E -0.9 0.3
P/B 0.5 2.9
ROE % -39.3 3.7
Net Margin % -33.5 3.8
Rev Growth 5Y % 0.7 10.0
D/E 1.4 0.2

Analyst Price Target

Hold
$21.50 +123.0%
Low: $20.00 High: $23.00
Forward P/E
4.2
Forward EPS
$2.28
EPS Growth (est.)
+0.0%
Est. Revenue
4.1 B

Earnings Estimates

Period EPS Est. Revenue Est. Analysts
FY2030 $2.92
$2.90 – $2.95
4.3 B 1
FY2029 $2.82
$2.80 – $2.85
4.2 B 1
FY2028 $2.67
$2.64 – $2.69
4.2 B 1

Key Takeaways

Revenue grew 0.68% annually over 5 years — modest growth
Generating 145.10M in free cash flow
Revenue growth is decelerating — 1Y growth trails 5Y average by 3.43%
Capital efficient — spends only 2.20% of revenue on capex
ROIC of 3.73% — low return on invested capital

Growth

Revenue Growth (5Y)
0.68%
Revenue (1Y)-2.75%
Earnings (1Y)N/A
FCF Growth (3Y)-30.89%

Quality

Return on Equity
-39.29%
ROIC3.73%
Net Margin-33.51%
Op. Margin8.07%

Safety

Debt / Equity
1.35
Current Ratio2.76
Interest Coverage2.11

Valuation

P/E Ratio
-0.93
P/B Ratio0.45
EV/EBITDA13.88
Dividend Yield0.08%

All Fundamental Metrics

Growth
Revenue Growth (1Y) -2.75% Revenue Growth (3Y) -4.42%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) 0.68% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 4.25B Net Income (TTM) -1.43B
ROE -39.29% ROA -16.70%
Gross Margin 35.14% Operating Margin 8.07%
Net Margin -33.51% Free Cash Flow (TTM) 145.10M
ROIC 3.73% FCF Growth (3Y) -30.89%
Safety
Debt / Equity 1.35 Current Ratio 2.76
Interest Coverage 2.11 Dividend Yield 0.08%
Valuation
P/E Ratio -0.93 P/B Ratio 0.45
P/S Ratio 0.31 PEG Ratio 0.00
EV/EBITDA 13.88 Dividend Yield 0.08%
Market Cap 1.33B Enterprise Value 4.76B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 4.25B 4.37B 4.66B 4.45B 4.14B
Net Income -1.43B -171.80M -12.70M -140.60M -68.90M
EPS (Diluted) -10.29 -1.25 -0.09 -0.97 -0.98
Gross Profit 1.49B 1.54B 1.68B 1.46B 1.42B
Operating Income 343.30M 112.90M 151.90M 78.90M 410.40M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 8.54B 9.65B 10.81B 11.02B 10.43B
Total Liabilities 5.60B 5.33B 6.04B 6.18B 5.27B
Shareholders' Equity 2.94B 4.32B 4.77B 4.84B 5.15B
Total Debt 3.97B 3.62B 4.07B 4.32B 3.69B
Cash & Equivalents 531.60M 558.80M 751.30M 600.70M 1.86B
Current Assets 2.80B 2.48B 2.83B 2.72B 3.86B
Current Liabilities 1.01B 1.04B 1.59B 1.11B 1.59B